FB
Fralin Biomedical Research Institute Cancer Research Center at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Fralin Biomedical Research Institute Cancer Research Center brings 2 presentations to ASH 2026 in New Orleans. Its program centres on detecting leftover leukemia cells, known as minimal residual disease. It covers molecular testing in myeloid cancers and a personalized DNA test for KMT2A-altered AML.
| Organization | ASH 2026 Attendance |
|---|---|
FB Fralin Biomedical Research Institute Cancer Research Center Washington, DC | |
Virginia Tech's cancer research center in Washington, DC, part of its Fralin Biomedical Research Institute. | Session Fri Dec 11 3:02pm–3:44pm Diseases and Mechanisms Newly described inherited disorders and how harmful germline variants disturb blood formation and lead to marrow failure or cancer. Talk Sun Dec 13 9:30am–10:45am Current Clinical Applications for Molecular MRD in Myeloid Malignancies Guidelines for testing leftover leukemia cells by their genetic markers, and the multi-country studies proving that acting on those results changes outcomes. Oral Sun Dec 13 9:30am–11:00am |
Find decision makers at Fralin Biomedical Research Institute Cancer Research Center
Tell us what you sell and we’ll find the people at Fralin Biomedical Research Institute Cancer Research Center most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction